[go: up one dir, main page]

ES2062990T3 - Vacunas, que contienen la proteina f del virus del sida. - Google Patents

Vacunas, que contienen la proteina f del virus del sida.

Info

Publication number
ES2062990T3
ES2062990T3 ES87401338T ES87401338T ES2062990T3 ES 2062990 T3 ES2062990 T3 ES 2062990T3 ES 87401338 T ES87401338 T ES 87401338T ES 87401338 T ES87401338 T ES 87401338T ES 2062990 T3 ES2062990 T3 ES 2062990T3
Authority
ES
Spain
Prior art keywords
vaccines
contain protein
aids
aids viruses
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87401338T
Other languages
English (en)
Inventor
Marie-Paule Kieny
Bruno Guy
Jean-Pierre Lecocq
Luc Montagnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Institut Pasteur
Original Assignee
Transgene SA
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA, Institut Pasteur filed Critical Transgene SA
Application granted granted Critical
Publication of ES2062990T3 publication Critical patent/ES2062990T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION SE REFIERE A UN VECTOR VIRICO CARACTERIZADO PORQUE INCLUYE AL MENOS: -UNA PARTE DEL GENOMA DE UN VIRUS; -UN GEN CODIFICANTE PARA LA PROTEINA F DEL VIRUS RESPONSABLE DEL SIDA, -ASI COMO LOE ELEMENTOS QUE ASEGURAN LA EXPRESION DE ESTA PROTEINA EN LAS CELULAS. ESTE VECTOR VIRICO PUEDE SER UTILIZADO COMO VACUNA EN EL TRATAMIENTO, LA PREVENCION Y EL DIAGNOSTICO DEL SIDA.
ES87401338T 1986-06-16 1987-06-15 Vacunas, que contienen la proteina f del virus del sida. Expired - Lifetime ES2062990T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8608698A FR2600079B1 (fr) 1986-06-16 1986-06-16 Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus

Publications (1)

Publication Number Publication Date
ES2062990T3 true ES2062990T3 (es) 1995-01-01

Family

ID=9336386

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87401338T Expired - Lifetime ES2062990T3 (es) 1986-06-16 1987-06-15 Vacunas, que contienen la proteina f del virus del sida.

Country Status (11)

Country Link
EP (1) EP0253693B1 (es)
JP (1) JPH01500962A (es)
KR (1) KR880701285A (es)
AT (1) ATE103980T1 (es)
AU (1) AU614934B2 (es)
DE (1) DE3789525T2 (es)
DK (1) DK76688D0 (es)
ES (1) ES2062990T3 (es)
FR (1) FR2600079B1 (es)
PT (1) PT85093B (es)
WO (1) WO1987007642A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2615623B1 (fr) * 1987-05-22 1992-06-19 Transgene Sa Test de diagnostic du sida base sur la mise en evidence d'une diversite de la reponse isotypique, vaccins et serotherapies
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
FR2629460B1 (fr) * 1988-04-01 1990-12-21 Pasteur Institut Peptides pf16 d'un retrovirus hiv - procede de synthese de ces peptides - leur utilisation pour le diagnostic
EP0349354A1 (fr) * 1988-04-01 1990-01-03 Institut Pasteur Peptides PF10 à PF19 d'un rétrovirus HIV, procédé de synthèse de ces peptides, leur utilisation notamment pour le diagnostic
FR2629459B1 (fr) * 1988-04-01 1990-12-21 Pasteur Institut Peptides pf11 a pf19 d'un retrovirus hiv - procede de synthese de ces peptides - leur utilisation notamment pour le diagnostic
US5221610A (en) * 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
WO1991018990A1 (fr) * 1990-05-28 1991-12-12 The Research Foundation For Microbial Diseases Of Osaka University Procede de preparation de plasmide ayant des capacites d'expression et de transformation apres translation d'un gene de retrovirus, plasmide ainsi obtenu, et produit d'expression d'un tel plasmide
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee

Also Published As

Publication number Publication date
WO1987007642A1 (fr) 1987-12-17
DE3789525T2 (de) 1994-08-25
EP0253693A1 (fr) 1988-01-20
JPH01500962A (ja) 1989-04-06
PT85093A (fr) 1987-07-01
EP0253693B1 (fr) 1994-04-06
AU7514087A (en) 1988-01-11
FR2600079B1 (fr) 1989-10-20
KR880701285A (ko) 1988-07-26
DK76688A (da) 1988-02-15
AU614934B2 (en) 1991-09-19
FR2600079A1 (fr) 1987-12-18
DK76688D0 (da) 1988-02-15
ATE103980T1 (de) 1994-04-15
PT85093B (pt) 1990-03-30
DE3789525D1 (de) 1994-05-11

Similar Documents

Publication Publication Date Title
DK0853660T3 (da) Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel
ES2124532T3 (es) Sistema vector-huesped utilizable en terapia genica.
ES2140418T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
ES2120036T3 (es) Virus recombinantes y su utilizacion en terapia genetica.
CY1106798T1 (el) Ανθρωπινα μεσεγχυματικα βλαστοκυτταρα απο περιφερειακο αιμα
ES2167365T3 (es) Vectores adenovirales de origen animal y utilizacion en terapia genica.
CA2243570A1 (en) Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv
DE60035778D1 (de) Rekombinante influenzaviren zur vakzinherstellung und gentherapie
ES2143507T3 (es) Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia.
ES2061520T3 (es) Expresion de un antigeno especifico de tumor por un virus vector recombinante y utilizacion de este para el tratamiento preventivo o curativo del tumor correspondiente.
EA200100302A1 (ru) Способы и композиции для протективной и терапевтической генетической иммунизации
AR248045A1 (es) Procedimiento para producir un virus de avipox recombinante, un cultivo de celulas eucariotica, una vacuna y para expresar la totalidad o parte de una proteina heterologa, secuencia de transferencia
ATE165345T1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
ES2062990T3 (es) Vacunas, que contienen la proteina f del virus del sida.
ES2052589T3 (es) Vector viral, codificante para una glicoproteina del virus responsable del sida, vacuna y anticuerpo.
HUP9901035A2 (hu) Idegen DNS-t tartalmazó parapoxvírusok, előállításuk és alkalmazásuk vakcinákban
CO4480038A1 (es) Virus de inmunodeficiencia felina geneticamente alterados y vacuna eficaz contra las infecciones del virus de inmunodeficiencia felina
ES8800985A1 (es) Procedimiento de preparar proteinas.
ES2118242T3 (es) Vacunas anti virus de la inmunodeficiencia felina (fiv).
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
ES2191842T3 (es) Interleucina-8 como agente antiviral y antitumoral.
ES2058116T3 (es) El virus varicella-zoster como una vacuna recombinante viva.
ES2054841T3 (es) Vector viral y adn recombinante que codifica para una o unas proteinas de estructura (ha, f y/o np), de un morbilivirus.
ES2140329A1 (es) Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 253693

Country of ref document: ES